Complete response of cutaneous metastasis in a melanoma patient treated with ipilimumab

Francesco Spagnolo, Serena Savaia, Marco Grosso, Paola Queirolo

Research output: Contribution to journalArticlepeer-review


We present the case of a 58 year old woman, who achieved complete response for her cu-taneous melanoma metastasis after treatment with ipilimumab at 3 mg/Kg. The patient was given dacarbazine as a first line treatment for her cutaneous metastasis and a partial response was achieved. However, after 26 cycles of chemotherapy, the cutaneous lesions progressed, so ipilimumab was chosen as a second line treatment. The patient was eligi-ble for the compassionate use of ipilimumab.Two weeks after the fourth cycle with ipilimumab, a complete response of most cutaneous metastasis was noted, with a partial response of the remaining lesions, which were still regressing at the last follow-up visit. Ipilimumab, which was recently reported to improve survival in patients with metastatic melanoma, represents a most promising immunotherapeutic drug and it has been ap-proved for patients with advanced melanoma as a first- and second-line treatment by the FDA and as a second-line treatment by the European Medicines Agency (EMA).

Original languageEnglish
Pages (from-to)3-6
Number of pages4
JournalEuroMediterranean Biomedical Journal
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Complete response of cutaneous metastasis in a melanoma patient treated with ipilimumab'. Together they form a unique fingerprint.

Cite this